| ²é¿´: 785 | »Ø¸´: 0 | ||
[ÇóÖú]
賦µÀºÍÒÈÏÙÉñ¾ÄÚ·ÖÃÚÖ×Áöϸ°ûϵµÄ½¨Á¢
|
|
ÔÚinnocentive.comÉÏ¿´µ½µÄÒ»¸öÌôÕ½ÏîÄ¿£¬³¦µÀÀà°©»òÒÈÏÙÉñ¾ÄÚ·ÖÃÚÖ×Áöϸ°ûϵ Intestinal Carcinoid and Pancreatic Neuroendocrine Tumor Cell Lines Needed ¨C Year Two Ò»Ö±Ïë×ö£¬½ØÖÁ7ÔÂ6ÈÕ£¬Ê±¼ä½ô£¬²»ÖªÓÐûÓÐÔÚ×Ô¼ºÎ¸³¦µÀÀà°©»òÒÈÏÙÉñ¾ÄÚ·ÖÃÚÖ×Áöϸ°ûϵµÄ£¿Ò»·½ÃæÊÇÍÆ¼ö£¬Ò»·½ÃæÊÇÓÐЩз½·¨ÏëÕÒʵÑéÊÒºÏ×÷¡£ BACKGROUND The majority of neuroendocrine tumors can be divided into two classes: carcinoid and pancreatic neuroendocrine tumors. Carcinoid commonly refers to neuroendocrine tumors that originate in the gastrointestinal (GI) tract, lungs, appendix and thymus, although they can also occur in the lymph nodes, brain, bone, gonads (ovaries and testes) and skin. Carcinoid tumors are usually indolent (slow-growing) by nature and develop over the course of many years. However, aggressive, fast-growing forms of carcinoid cancer also exist. Neuroendocrine tumors are classified as rare cancers. Recent studies have determined that 4 to 5 out of every 100,000 people are diagnosed yearly with a neuroendocrine tumor and that there are over 100,000 people currently living with neuroendocrine tumors within the United States (Yao et al., 2009). For reasons not well understood, the incidence of these cancers is rising. Since most individuals with neuroendocrine tumors are asymptomatic until the tumors metastasize, the average time between tumor development and diagnosis is between 5 to 10 years (Vinik, 2008; Vinik et al., 2009). Survival rates for individuals with neuroendocrine cancer vary and depend on tumor type, location, extent of metastases, and many other factors. Currently, surgery is the only cure for localized tumors (those which have not spread) and there is no cure for metastatic neuroendocrine cancer (Yao, 2007). This Challenge is intended to encourage development of intestinal carcinoid and pancreatic neuroendocrine tumor cell lines. ÎÒµÄÓÊÏäÊÇ£ºagilebio@126.com |
» ²ÂÄãϲ»¶
¿ÎÌ⸺ÔðÈ˲»ÊǵÚÒ»»òÕßͨѶ×÷Õߣ¬ÄÜÓÃÓÚÖÐÆÚ¿¼ºË»òÕß½áÌâÂð£¿
ÒѾÓÐ5È˻ظ´
ÇóÎÊʲôζȼƿÉÒÔ²âÁ¿Ð¡Êó¸ØÎ£¨µÍÓÚ32¡æ£©£¿
ÒѾÓÐ3È˻ظ´
ҽѧÃâÒßѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ60È˻ظ´
ÇóһЩµ°°×±£»¤ÐÔÉϵ÷£¬×îºóËæ×ż²²¡·¢Õ¹ÓÖϽµµÄÎÄÏ×£¡
ÒѾÓÐ0È˻ظ´
¼ÃÄÏ´óѧÌìȻҩÎﻯѧÉúÎïѧÍŶÓÕÐÊÕ¡°Ò©Ñ§¡±×¨Ë¶µ÷¼ÁÉú
ÒѾÓÐ0È˻ظ´
¼ÃÄÏ´óѧÕÅ»ª½ÌÊÚÕÐÊÕµ÷¼ÁÉú
ÒѾÓÐ0È˻ظ´











»Ø¸´´ËÂ¥
10